Ewing Sarcoma - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 159 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Ewing Sarcoma - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Ewing Sarcoma - Pipeline Review, H2 2015', provides an overview of the Ewing Sarcoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ewing Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ewing Sarcoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Ewing Sarcoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Ewing Sarcoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Ewing Sarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Ewing Sarcoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Ewing Sarcoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Ewing Sarcoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Ewing Sarcoma Overview 10
Therapeutics Development 11
Pipeline Products for Ewing Sarcoma - Overview 11
Pipeline Products for Ewing Sarcoma - Comparative Analysis 12
Ewing Sarcoma - Therapeutics under Development by Companies 13
Ewing Sarcoma - Therapeutics under Investigation by Universities/Institutes 15
Ewing Sarcoma - Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Ewing Sarcoma - Products under Development by Companies 18
Ewing Sarcoma - Products under Investigation by Universities/Institutes 19
Ewing Sarcoma - Companies Involved in Therapeutics Development 20
Cebiotex, S.L. 20
EntreChem, S.L. 21
Exelixis, Inc. 22
Gradalis Inc. 23
Kolltan Pharmaceuticals, Inc. 24
Merck & Co., Inc. 25
Merrimack Pharmaceuticals, Inc. 26
NanoSmart Pharmaceuticals, Inc. 27
Nanovalent Pharmaceuticals Inc. 28
NantKwest, Inc. 29
Novartis AG 30
Oncomatryx Biopharma, S.L. 31
Recombio S.L 32
Shionogi & Co., Ltd. 33
Sigma-Tau S.p.A. 34
Tesaro, Inc. 35
Tokalas, Inc. 36
Ewing Sarcoma - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Target 38
Assessment by Mechanism of Action 41
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 47
cabozantinib s-malate - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
CEB-01 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
celyvir - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
dactinomycin next generation - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Drugs to Inhibit Sirtuin 1 for Ewing Sarcoma - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
EC-8042 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
EC-8105 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
everolimus - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
gemogenovatucel-T - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
haNK Program - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
irinotecan hydrochloride - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
KIT-SG3227 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Monoclonal Antibody Conjugated for Ewing Sarcoma - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Monoclonal Antibody to Inhibit GD2 for Oncology - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
niraparib - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
NV-101 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
OMTX-503 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
OMTX-703 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
pazopanib hydrochloride - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
pembrolizumab - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
racotumomab - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
roneparstat - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
S-588410 - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Small Molecules for Ewing Sarcoma - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
SP-2509 - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
SP-2528 - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
SP-2577 - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
TK-216 - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
YK-4279 - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
Ewing Sarcoma - Recent Pipeline Updates 108
Ewing Sarcoma - Dormant Projects 152
Ewing Sarcoma - Discontinued Products 153
Ewing Sarcoma - Product Development Milestones 154
Featured News & Press Releases 154
Oct 09, 2015: Novel compound turns off mutant cancer gene in animals with leukemia 154
Jul 30, 2015: NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 154
Jun 04, 2015: Gradalis Announces Presentation of Data from a Pilot Study of Vigil Cancer Vaccine in Ewing's Sarcoma 155
Feb 11, 2015: NanoSmart Receives FDA Orphan Drug Designation for ANA-Conjugated Liposomal Doxorubicin for the Treatment of Ewing's Sarcoma 155
Nov 26, 2012: Possible New Treatment for a Childhood Cancer 156
Apr 16, 2012: EntreChem's Mithramycin Analog EC-8042 Shows Increased Potency And High Selectivity For Treatment Of Sarcoma 157
Apr 16, 2012: EntreChem's Mithramycin Shows Increased Potency and Higher Selectivity For Treatment Of Sarcoma 157
Appendix 158
Methodology 158
Coverage 158
Secondary Research 158
Primary Research 158
Expert Panel Validation 158
Contact Us 158
Disclaimer 159

List of Tables

Number of Products under Development for Ewing Sarcoma, H2 2015 11
Number of Products under Development for Ewing Sarcoma - Comparative Analysis, H2 2015 12
Number of Products under Development by Companies, H2 2015 14
Number of Products under Investigation by Universities/Institutes, H2 2015 15
Comparative Analysis by Clinical Stage Development, H2 2015 16
Comparative Analysis by Early Stage Development, H2 2015 17
Products under Development by Companies, H2 2015 18
Products under Investigation by Universities/Institutes, H2 2015 19
Ewing Sarcoma - Pipeline by Cebiotex, S.L., H2 2015 20
Ewing Sarcoma - Pipeline by EntreChem, S.L., H2 2015 21
Ewing Sarcoma - Pipeline by Exelixis, Inc., H2 2015 22
Ewing Sarcoma - Pipeline by Gradalis Inc., H2 2015 23
Ewing Sarcoma - Pipeline by Kolltan Pharmaceuticals, Inc., H2 2015 24
Ewing Sarcoma - Pipeline by Merck & Co., Inc., H2 2015 25
Ewing Sarcoma - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2015 26
Ewing Sarcoma - Pipeline by NanoSmart Pharmaceuticals, Inc., H2 2015 27
Ewing Sarcoma - Pipeline by Nanovalent Pharmaceuticals Inc., H2 2015 28
Ewing Sarcoma - Pipeline by NantKwest, Inc., H2 2015 29
Ewing Sarcoma - Pipeline by Novartis AG, H2 2015 30
Ewing Sarcoma - Pipeline by Oncomatryx Biopharma, S.L., H2 2015 31
Ewing Sarcoma - Pipeline by Recombio S.L, H2 2015 32
Ewing Sarcoma - Pipeline by Shionogi & Co., Ltd., H2 2015 33
Ewing Sarcoma - Pipeline by Sigma-Tau S.p.A., H2 2015 34
Ewing Sarcoma - Pipeline by Tesaro, Inc., H2 2015 35
Ewing Sarcoma - Pipeline by Tokalas, Inc., H2 2015 36
Assessment by Monotherapy Products, H2 2015 37
Number of Products by Stage and Target, H2 2015 39
Number of Products by Stage and Mechanism of Action, H2 2015 42
Number of Products by Stage and Route of Administration, H2 2015 44
Number of Products by Stage and Molecule Type, H2 2015 46
Ewing Sarcoma Therapeutics - Recent Pipeline Updates, H2 2015 108
Ewing Sarcoma - Dormant Projects, H2 2015 152
Ewing Sarcoma - Discontinued Products, H2 2015 153